Skip to main content
SpringerLink
Log in

Haemorrhages and anticoagulants the responsibility of the patient

  • Chapter
Anticoagulation

  • 58 Accesses

Abstract

Even using sophisticated methods like monograms for heparin and (INR-ISI) system for OA, the risk of bleeding persists during antithrombotic treatments. In most of the cases, it is reported to an overdosage, and that is true in some cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albada J, Nieuwenhuis HK, Sixma JS. Treatment of acute venous thrombo-embolism with low molecular weight heparin (fragmin) — Results of a double-blind randomized study. Circulation 4, 935–940, 1980.

    Google Scholar 

  2. Arcelus JI, Caprini JA, Traverso CI. International perspective on venous thromboembolism prophylaxis in surgery. Semin Thromb Haemostas 4, 17, 322–325, 1991.

    Article  Google Scholar 

  3. Biemer JJ. Control of oral anticoagulant therapy. Ann Clin Lab Sei 18, 6, 421–428, 1988.

    CAS  Google Scholar 

  4. Conti S. Letter to editor. The West J Med 137(1), 81, 1982.

    CAS  Google Scholar 

  5. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM. Prevention of deep venous thrombosis in elderly medical patients by a low molecular weight heparin: a randomized double blind trial. Haemostasis 16, 159–164, 1986.

    PubMed  CAS  Google Scholar 

  6. Demichelis C, Cohen S, Braguer D, Juhan-Vague I, Aillaud MF. Utilité de la surveillance biologique de 1’héparinothérapie à visée curative. J Pharm Clin 3, 3–4, 367–373, 1984.

    Google Scholar 

  7. Derlon A, Fressinger JN. Coordinators. Utilisation des antivitamines K en pratique médicale courante. Recommandations du GEHT. STV (Suppl 3), 5, 11–15, 1991.

    Google Scholar 

  8. Deykin D, Salzman EW, Mayer R. Prospective study of complications of heparin therapy ISTH Congres — Washington D.C. 1972.

    Google Scholar 

  9. Doutemepuich C, Toulemonde F, Bousquet F, Bonini F. Comparison of the haemorragic effects of unfractionated heparin and a low molecular weight heparin fraction, CY 216, in rabbits. Thromb Res 43, 691–695, 1986.

    Article  Google Scholar 

  10. Etude Multicentrique Francaises. Traitement des thromboses veineuses profondes constituées — Etude comparative d’un fragment d’;heparine de bas poids moleculaire (fragmine) par voie SC et de 1’héparine standard administrée par voie veineuse continue. Rev Med Interne 10, 375–381, 1989.

    Article  Google Scholar 

  11. Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, Toulemonde F, Bassand JP, Maurat JP. Un nouveau traitement des thromboses veineuses profondes, les fractions d’héparine de bas poids moléculaire — Etude randomisée. Presse Med 17, 197–200, 1988.

    PubMed  CAS  Google Scholar 

  12. Forfar JC. A 7 year analysis of haemorrhage in patients on long term anticoagulant treatment Biol Mol J 42, 128–132, 1979.

    CAS  Google Scholar 

  13. Franke CL, de Jonge J, van Swieten JC, OP de Coul AAW, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 21(5), 726–730, 1990.

    CAS  Google Scholar 

  14. Glazier RL, Crowell EB. Randomized prospective trial of continuous versus intermittent heparin therapy. JAMA 236(12), 1365–1367, 1976.

    Article  PubMed  CAS  Google Scholar 

  15. Harenberg J, Huck K, Bratsch H, Stehle G, Dempfe CE, Mall K, Blauth M, Vsadel KH, Heene DL. Therapeutic application of subcutaneous LMWH heparin in acute venous thrombosis. Haemostasis 20 (Suppl 1), 205–219, 1990.

    PubMed  Google Scholar 

  16. Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kubler W. Long term anticoagulation with low molecular weight heparin in out patients with side effects on oral anticoagulants. Nouv Rev Fr Hematol 31, 363–369, 1989.

    PubMed  CAS  Google Scholar 

  17. Heiden D, Rodvier R, Harold Mielke C Heparin bleeding, platelet dysfunction and aspirin. JAMA 216(4), 330–333, 1981.

    Article  Google Scholar 

  18. Hirsh J, Levine MN. Low molecular weight heparin. Blood 79(1), 1–18, 1992.

    PubMed  CAS  Google Scholar 

  19. Hirsh J. Oral anticoagulant drugs. N Engl J Med 324, 1865–1875, 1991.

    Article  PubMed  CAS  Google Scholar 

  20. Hoek J, Nurmohamed MT, Ten Cate H, Ten Cate JW, Buller HR. Prevention of deep vein thrombosis following total hip replacement by a low-molecular-weight heparinoid (Org 10172). Thromb Haemost 62, 520 (Abstr.), 1989.

    Google Scholar 

  21. Hull R, Hirsh J, Jay R, Carter C, England C Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 307, 1676–1681, 1982.

    Article  PubMed  CAS  Google Scholar 

  22. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 92(2), 375–515, 1989.

    Google Scholar 

  23. ICTH-ISTH. Report of the expert panel on oral anticoagulant control. Thromb Haemost 42, 1073–1114, 1979.

    Google Scholar 

  24. Kher A, Toulemonde F. Examen simplifié de l’hémostase in pré-operatoire. Gaz Med de France 81, 1877–1883, 1974.

    Google Scholar 

  25. Landefeld C, S Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 82, 703–713, 1987.

    CAS  Google Scholar 

  26. Landefeld CS, Goldman L. Major bleeding in out patients treated with Warparin: incidence and prediction by factors known at the start of out patient therapy. Am J Med 87, 144–152, 1989.

    Article  PubMed  CAS  Google Scholar 

  27. Landefeld CS, McGuire E, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 89, 569–578, 1990.

    Article  PubMed  CAS  Google Scholar 

  28. Landefeld CS, Rosenblatt MW. Bleeding in out patients heated with Warparin: relation to the prothrombin time and important remediable lesions. Am J Med 87, 153–159, 1989.

    Article  PubMed  CAS  Google Scholar 

  29. Lassen MR, Borris LC, Christiansen HM, Schott P, Olsen AD, Sorensen JV, Rahr H, Jensen HP. Clinical trials with low molecular weight heparins in the prevention of postoperative thrombo-embolic complications — A meta analysis. Semin. Thromb Haemost 17(Suppl 3), 284–290, 1991.

    Google Scholar 

  30. Launbjerg J, Egeblad H, Heaf J, Nielsen NH. Bleeding complications to oral anticoagulant therapy: mulivariate analysis of 1010 treatment years in 551 out patients. J Int Med 229, 351–3555, 1991.

    Article  CAS  Google Scholar 

  31. Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Haemostas 12(1), 39–57, 1986.

    Article  CAS  Google Scholar 

  32. Levine MN, Hirsh J, Kelton JG. Heparin induced bleeding. In: Lane D, Lindhahl U (Eds). Heparin: — Chemical and Biol, properties, — Clinical applications. E. Arnold, London, pp 517–531. 1989.

    Google Scholar 

  33. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long term anticoagulant therapy. Chest 89(2), 163–255, 1986.

    Article  Google Scholar 

  34. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long term anticoagulant therapy. Chest 95(2), 265–365, 1989.

    Google Scholar 

  35. Mant MJ, O Brien BD, Thong KL, Hammond GW et al. Haemorrhagic complications of heparin therapy. Lancet 8022, 1133–1136, 1977.

    Google Scholar 

  36. Morabia A. Heparin doses and major bleedings. Lancet 1, 8492, 1278–1279, 1986.

    Article  PubMed  CAS  Google Scholar 

  37. Mottironi SC, Selz Y. Hypersensibilité à l’héparine ou le Chirurgien et les hématomes. Med et Hyg 43, 2659–2660, 1985.

    Google Scholar 

  38. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification for risk factors for bleeding during treatment of acute venous thrombo-embolism with heparin or LMWH. Blood 78(9), 2337–2343, 1991.

    PubMed  CAS  Google Scholar 

  39. Nitter-Hange S, Dale J. High complication and failure rates of anticoagulant therapy are unavoidable. Z Kardiologie 75(Suppl 2), 293–297, 1986.

    Google Scholar 

  40. Ockelford PA, Kesteren PJ, Patterson J, Brand N, Johns A. A double blind placebo controlled trial to study the efficacy and safety of a low molecular weight heparin fragment (Fragmin) in patients having major elective hip surgery. Thromb Res (Suppl. VII-B) 23, 19, 1987.

    Article  Google Scholar 

  41. Ockelford PA, Patterson J, John AS. A double blind randomized placebo controlled trial of thrombo-prophylaxis in major elective general surgery using once daily injections of LMW heparin fragment (Fragmin). Thromb Haemostas 62(4), 1046–1049, 1989.

    CAS  Google Scholar 

  42. Petitti DB, Storm BL, Melmon KL. Duration of Warparin anticoagulant therapy and the probabilities of recurrent thrombo-embolism and hemorrhage. Am J Med 81, 225–259, 1986.

    Article  Google Scholar 

  43. Peyman M. The significance of hemorrhage during the treatment with Coumarin anticoagulants. Acta Med Scand 162, 339, 1–62, 1958.

    Article  Google Scholar 

  44. Pezzuoli G, Neri Serneri GG, Settembrini PG, STEP Study Group. Effectiveness and safety of the LMWH CY 216 in the prevention of fatal pulmonary embolism and thrombo-embolic death in general surgery. Haemostasis 20(Suppl 1), 193–204, 1990.

    PubMed  Google Scholar 

  45. Pollard JW, Hamilton MJ, Christensen NA, Achor RWP. Problems associated with long-term anticoagulant therapy. Circulation 25, 311–317, 1962.

    PubMed  CAS  Google Scholar 

  46. Samama CM. Bilan d’;hémostase pré-opératoire: Quoi de neuf? JEPU — Arnette Paris 105–112, 1990.

    Google Scholar 

  47. Shetty HGM, Backhouse G, Bentley DP, Routledge PA. Effective reversal of Warpar in-induced excessive ant icoagu1at ion with low dose vitamin Kl. Thromb Haemost 67(1), 13–15, 1992.

    PubMed  CAS  Google Scholar 

  48. Torholm C, Broeng L, Seest Jorgensen P et al. Thromboprophylaxis by low—molecular—weight heparin in elective hip surgery. J Bone Joint Surg (Br) 73, 434–438, 1991.

    CAS  Google Scholar 

  49. Toulemonde F. Can the bleeding potential of low molecular weight heparins be assessed and minimized in post surgery prophylaxis ? Semin Thromb Haemostas 17(Suppl 4), 351–356, 1991.

    Article  CAS  Google Scholar 

  50. Turpie A, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. Arandomized controlled trial of a low molecular weight heparin (Enoxaparine) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315, 925–929, 1986.

    Article  PubMed  CAS  Google Scholar 

  51. Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 244(11), 1209–1212, 1980.

    Article  PubMed  CAS  Google Scholar 

  52. Watson CJE, Deane AM, Doyle PT, Bullock KN. Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin Brit J Urol 66, 85–87, 1990.

    CAS  Google Scholar 

  53. Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J 77(2), 155–158, 1979.

    Article  Google Scholar 

  54. Wolf H, Encke A, Haas S, Welzel D. Comparison of the efficacy and safety of Sandoz LMW heparin and unfractionated heparin: interim analysis of a multicenter trial. Semin Thromb Haemostas 17(Suppl 4), 343–346, 1991.

    Article  CAS  Google Scholar 

Download references

Authors
  1. F. Toulemonde
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratoire d’Hematologie, 3, Place de la Victoire, 33076, Bordeaux cedex, France

    Christian Doutremepuich

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Toulemonde, F. (1994). Haemorrhages and anticoagulants the responsibility of the patient. In: Doutremepuich, C. (eds) Anticoagulation. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2668-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2668-0_28

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7627-2

  • Online ISBN: 978-1-4612-2668-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation